

BIOGEN IDEC - Dominating Multiple Sclerosis Market for Long Term!

<https://marketpublishers.com/r/B24066AF5B9EN.html>

Date: October 2011

Pages: 4

Price: US\$ 90.00 (Single User License)

ID: B24066AF5B9EN

Abstracts

Delay in FDA action – review on the inclusion of anti-JC virus – REMS programs for Tysabri, was offset by the data presented atECTRIMS ‘11 on BG-12 and Daclizumab (stock up by 6-8%). We expect the earnings also to please investors and with a robust cash position (total cash: \$2.1b and yearly FCF of ~\$1.3b), and with Tysabri, Fampyra, BG-12 (PhIII), Daclizumab (PhII), PEG-IFN b-1a (PhIII), BIIB should retain its leadership in the MS space. For more detail, please read our report released on 25th October, 2011 on BIIB titled “Dominating Multiple Sclerosis Market for Long Term!”

Contents

COMPANIES MENTIONED

BIOGEN IDEC

I would like to order

Product name: BIOGEN IDEC - Dominating Multiple Sclerosis Market for Long Term!

Product link: <https://marketpublishers.com/r/B24066AF5B9EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B24066AF5B9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970